Granted Patent
B2
US 12,233,116 · App. 18/896,286 · Granted Feb 25, 2025
IL-15-based fusions to IL-12 and IL-18
Inventors:
Warren D. Marcus (Miramar, FL); Robert Newman (Miramar, FL); Bai Liu (Cooper City, FL); Lijing You (Miramar, FL); Lin Kong (Miramar, FL); Peter Rhode (Miami, FL); Hing C. Wong (Weston, FL)
Assignee:
Altor Bioscience, LLC.
A61K39/00114A61K39/4613A61K39/46444A61K47/6811A61P35/00C07K14/54C07K14/5434C07K14/5443C07K14/715C07K16/283C12N15/62A61K2239/31A61K2239/38A61K2239/48C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
Claims (8)
1. A pharmaceutical composition comprising natural killer (NK) cells and
an isolated soluble fusion protein complex comprising a first soluble protein comprising an interleukin-15 (IL-15) polypeptide domain and an IL-18 polypeptide domain, and a second soluble protein comprising a soluble IL-15 receptor alpha sushi (IL-15RαSu) polypeptide domain and an IL-12 polypeptide domain, wherein the IL-15 polypeptide domain binds to the IL-15RαSu polypeptide domain to form the soluble fusion protein complex,
wherein the pharmaceutical composition is formulated for administration.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for administration by instillation into the bladder, or subcutaneous, intravenous, intraperitoneal, intramuscular, intratumoral or intradermal injection.
3. The pharmaceutical composition of claim 1 , wherein the composition further comprises an immunotherapy, an adoptive cell therapy, a vaccine, an antibody, radiation therapy, or a chemotherapy.
4. The pharmaceutical composition of claim 3 , wherein the antibody is specific for a checkpoint inhibitor, a neoantigen, a tumor associated antigen, or a tumor specific antigen.
5. The pharmaceutical composition of claim 1 , wherein the isolated soluble fusion protein complex is formulated in an amount between 1 mg/kg and 100 mg/kg.
6. The pharmaceutical composition of claim 1 , wherein the NK cells are formulated in an amount of 1×10 4 cells/kg and 1×10 10 cells/kg.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 24, 2024
From: MARCUS, WARREN D.; NEWMAN, ROBERT G.; LIU, BAI; YOU, LIJING; KONG, LIN; RHODE, PETER
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 069009/0008 →
MERGER
Recorded Oct 24, 2024
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE, LLC.
Reel/Frame 069009/0029 →
CONSULTING AGREEMENT
Recorded Oct 24, 2024
From: WONG, HING C.
To: ALTOR BIOSCIENCE, LLC.
Reel/Frame 069270/0716 →
Continuity (8)
Provisional Application
62467623
· Mar 6, 2017
References Cited (118)
US 5116964A
· Capon et al.
· 1992
[cited by applicant]
US 5541087A
· Lo et al.
· 1996
[cited by applicant]
US 5620939A
· Haisa et al.
· 1997
[cited by applicant]
US 5891680A
· Leschke et al.
· 1999
[cited by applicant]
US 8163879B2
· Wong et al.
· 2012
[cited by applicant]
US 8492118B2
· Wong et al.
· 2013
[cited by applicant]
US 8507222B2
· Wong et al.
· 2013
[cited by applicant]
US 8940289B2
· Wong et al.
· 2015
[cited by applicant]
US 9255141B2
· Wong et al.
· 2016
[cited by applicant]
US 9328159B2
· Wong et al.
· 2016
[cited by applicant]
US 9428573B2
· Wong et al.
· 2016
[cited by applicant]
US 9464127B2
· Wong et al.
· 2016
[cited by applicant]
US 9925247B2
· Liu et al.
· 2018
[cited by applicant]
US 20040219096A1
· De Waal Malefyt et al.
· 2004
[cited by applicant]
US 20050063945A1
· Paul
· 2005
[cited by applicant]
US 20080300188A1
· Yang et al.
· 2008
[cited by applicant]
US 20100303811A1
· Ochi
· 2010
[cited by applicant]
US 20140242025A1
· Wong et al.
· 2014
[cited by applicant]
US 20150017121A1
· Becher et al.
· 2015
[cited by applicant]
US 20150374790A1
· Liu et al.
· 2015
[cited by applicant]
US 20190048055A1
· Shrestha et al.
· 2019
[cited by applicant]
US 20240252609A1
· Marcus et al.
· 2024
[cited by applicant]
JP 2006514057
· 2006
[cited by applicant]
JP 2011045375
· 2011
[cited by applicant]
JP 2013541335
· 2017
[cited by applicant]
WO WO9404689
· 1994
[cited by applicant]
WO WO9429350
· 1994
[cited by applicant]
WO WO9632478
· 1996
[cited by applicant]
WO WO9734631
· 1997
[cited by applicant]
WO WO2005046449
· 2005
[cited by applicant]
WO WO2012040323
· 2012
[cited by applicant]
WO WO2013053775
· 2013
[cited by applicant]
WO WO2018165208
· 2018
[cited by applicant]
U.S. Appl. No. 15/913,837, filed Mar. 6, 2018 now U.S. Pat. No. 11,129,883.
[cited by applicant]
U.S. Appl. No. 17/486,683, filed Sep. 27, 2021 now U.S. Pat. No. 11,571,470.
[cited by applicant]
U.S. Appl. No. 17/820,980, filed Aug. 19, 2022 now U.S. Pat. No. 11,612,645.
[cited by applicant]
U.S. Appl. No. 18/168,428, filed Feb. 13, 2023 now U.S. Pat. No. 11,872,272.
[cited by applicant]
U.S. Appl. No. 18/526,598, filed Dec. 1, 2023 now U.S. Pat. No. 11,975,059.
[cited by applicant]
U.S. Appl. No. 18/611,464, filed Mar. 20, 2024.
[cited by applicant]
Benton et al. (Apr. 8, 1977) “Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ”, Science, 196(4286):180-182.
[cited by applicant]
Berrien-Elliott et al., “Human Cytokine-Induced Memory-Like Natural Killer Cells,” Journal of Innate Immunity, Apr. 30, 2015, vol. 7(6), pp. 563-571.
[cited by applicant]
Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research, 2000, 10:398-400 (Year: 2000).
[cited by applicant]
Bowie et al. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. Science, 1990, 247:1306-1310 (Year: 1990).
[cited by applicant]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L…
[cited by applicant]
Capon et al. (Feb. 9, 1989) “Designing CD4 Immunoadhesins for AIDS Therapy”, Nature, 337(6207):525-531.
[cited by applicant]
Cerwenka et al. (Feb. 2016, e-published on Jan. 25, 2016) “Natural Killer Cell Memory in Infection, Inflammation and Cancer”, Nature Reviews Immunology, 16(2):112-123.
[cited by applicant]
Chamow et al. (Feb. 1996) “Immunoadhesins: Principles and Applications”, Trends Biotechnology, 14:52-60.
[cited by applicant]
Chang et al. (Jan. 2013) “Donor Lymphocyte Infusions for Relapse After Allogeneic Transplantation. When, If and for Whom?”, Blood Reviews, 27(1):55-62.
[cited by applicant]
Chirifu et al. (Sep. 2007, e-published on Jul. 22, 2007) “Crystal Structure of the IL-15-IL-15RαComplex, a Cytokine-Receptor Unit Presented in Trans”, Nature Immunology, 8(9):1001-1007.
[cited by applicant]
Database Genbank (Dec. 19, 1995) “Human Interleukin-15 Receptor Alpha Chain Precursor (IL15RA) mRNA, Complete cds”, GenBank Accession No. U31628.1, 2 pages.
[cited by applicant]
Database Genbank (May 20, 2005) “Mus Musculus Interleukin 15 Receptor, Alpha Chain, mRNA (cDNA clone IMAGE:4457379), Complete cds”, GenBank Accession No. BC095982.1, 2 pages.
[cited by applicant]
Database Genbank (Sep. 14, 1995) “Mus Musculus Interleukin 15 (IL15) mRNA, Complete cds”, GenBank Accession No. U14332.1, 2 pages.
[cited by applicant]
Database Genbank (Sep. 21, 1994) “Human Interleukin 15 (IL15) mRNA, complete cds”, GenBank Accession No. U14407.1, 2 pages.
[cited by applicant]
Davis (1985) “Molecular Genetics of the T Cell-receptor Beta Chain”, Annual Review of Immunology, 3:537-560.
[cited by applicant]
Dubois et al., The Journal Immunology, 2016; vol. 197, pp. 168-178.
[cited by applicant]
Ellison et al. (Jul. 10, 1982) “The Nucleotide Sequence of a Human immunoglobulin Cyl Gene”, Nucleic Acids Research, 10(13):4071-4079.
[cited by applicant]
Fehninger et al. (Dec. 2016) “Harnessing NK Cell Memory for Cancer immunotherapy”, Trends in Immunology, 37(12):877-888.
[cited by applicant]
Fleer (Oct. 1992) “Engineering Yeast for High Level Expression”, Current Opinion in Biotechnology, 3(5):486-496.
[cited by applicant]
Frankel et al. (Oct. 2000) “Cell Surface Receptor-Targeted Therapy of Acute Myeloid Leukemia: A Review”, Cancer Biotherapy & Radiopharmaceuticals, 15(5):459-476.
[cited by applicant]
Gerber et al. (May/Jun. 2009) “Antibody Drug-Conjugates Targeting the Tumor Vasculature-Current And Future Developments”, mAbs, 1(3):247-253.
[cited by applicant]
Gillies, Stephen D., et al. “Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases.” The Journal of Immunology 160.12 (1998): 6195-6203.
[cited by applicant]
Graham et al. (Jul. 1977) “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”, Journal of General Virology, 36(1):59-72.
[cited by applicant]
Greenspan et al. 1999. Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937 (Year: 1999).
[cited by applicant]
Grunstein et al. (Oct. 1975) “Colony Hybridization: A Method for the Isolation of Cloned DNAs That Contain a Specific Gene”, Proceedings of the National Academy of Sciences of the United States of America, 72(10):3961-3…
[cited by applicant]
Guillerey et al. (2016, e-published on Aug. 19, 2016) “Targeting Natural Killer Cells in Cancer immunotherapy”, Nature Immunology, 17:1025-1036.
[cited by applicant]
Guo et al. (2013) “Therapeutic Cancer Vaccines: Past, Present and Future”, Advances in Cancer Research, 119:421-475.
[cited by applicant]
Han et al. (Dec. 2011, e-published on Oct. 22, 2011) “IL-15:IL-15 Receptor Alpha Superagonist Complex: High-Level Co-Expression in Recombinant Mammalian Cells, Purification and Characterization”, Cytokine, 56(3):804-810.
[cited by applicant]
Hu et al. (Feb. 2018, e-published on Sep. 7, 2017) “Chimeric Antigen Receptor (CAR)-Transduced Natural Killer Cells in Tumor immunotherapy”, Acta Pharmacologica Sinica, 39:167-176.
[cited by applicant]
Irving et al. (Apr. 3, 2017) “Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel”, Frontiers in immunology, 8(267):19 pages.
[cited by applicant]
Kim et al. (Mar. 13, 2001) “Site-Specific Mutations in The Mature Form of Human IL-18 with Enhanced Biological Activity and Decreased Neutralization by IL-18 Binding Protein”, PNAS, 98(6):3304-3309.
[cited by applicant]
Kimmel (1987) “Identification and Characterization of Specific Clones: Strategy for Confirming the Validity of Presumptive Clones”, Methods in Enzymology, 152:507-511.
[cited by applicant]
Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988).
[cited by applicant]
Leong et al. (Feb. 4, 2003) “Optimized Expression and Specific Activity of IL-12 by Directed Molecular Evolution”, PNAS, 100(3):1163-1168.
[cited by applicant]
Leong, Jeffrey W., et al. “Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.” Biology of Blood and Marrow Tr…
[cited by applicant]
Liew et al. (Nov. 1, 2002) “Role of Interleukin 15 and Interleukin 18 in Inflammatory Response”, Annals of the Rheumatic Diseases, 61 (suppl 2):100-102.
[cited by applicant]
Mikayama et al. Proc. Natl. Acad. Sci. USA (1993) vol. 90, pp. 10056-10060.
[cited by applicant]
Moskaug et al. (Sep. 15, 1989) “Translocation of Diphtheria Toxin A—Fragment to the Cytosol. Role of The Site of Interfragment Cleavage”, Journal of Biological Chemistry, 264(26):15709-15713.
[cited by applicant]
Ni et al. (2012) “Sustained Effector Function of IL-12/15/18-Preactivated NK Cells against Established Tumors”, Journal of Experimental Medicine, 209(13):2351-2365.
[cited by applicant]
Ni et al., “Toward the next generation of NK cell-based adoptive cancer immunotherapy,” Oncolmmunology, Apr. 2013, vol. 2(4), pp. e23811-1-e23811-3.
[cited by applicant]
Novellino et al. (e-published on Aug. 7, 2004) “A Listing of Human Tumor Antigens Recognized by T Cells: Mar. 2004 Update”, Cancer Immunology, immunotherapy, 54(3):187-207.
[cited by applicant]
Oleksiewicz et al. (e-published on Jun. 13, 2012) “Anti-bacterial Monoclonal Antibodies: Back to the Future?”, Archives of Biochemistry and Biophysics, 526(2):124-131.
[cited by applicant]
Olsnes et al. (1982) “Chimeric Toxins”, Pharmacology and Therapeutics, 15(3):355-381.
[cited by applicant]
Pardoll (Apr. 2012) “The Blockade of Immune Checkpoints in Cancer immunotherapy”, Nature Reviews Cancer, 12(4):252-264.
[cited by applicant]
Parmiani et al. (2007) “Unique Human Tumor Antigens: immunobiology and Use in Clinical Trials”, The Journal of Immunology, 178(4):1975-1979.
[cited by applicant]
Pastan et al. (1992) “Recombinant Toxins as Novel Therapeutic Agents”, Annual Review Biochemistry, 61:331-354.
[cited by applicant]
Pastan et al. (Dec. 5, 1986) “immunotoxins”, Cell, 47:641-648.
[cited by applicant]
Rager et al. (Sep. 5, 2011) “Cellular Therapy Following Allogeneic Stem-Cell Transplantation”, Therapeutic Advances in Hematology, 2(6):409-428.
[cited by applicant]
Roddie et al. (Jan. 27, 2011) “Donor Lymphocyte Infusion Following Allogeneic Hematopoietic Stem Cell Transplantation”, Expert Opinion on Biological Therapy, 11(4):473-487.
[cited by applicant]
Romee et al. (Sep. 21, 2016) “Cytokine-Induced Memory-like Natural Killer Cells Exhibit Enhanced Responses against Myeloid Leukemia”, Science Translational Medicine,8(357):13 pages.
[cited by applicant]
Rueff et al. (Jun. 2014) “Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma”, Biology of Blood and Marrow Transplantation, 20(6):896-899.
[cited by applicant]
Sliwkowski et al. (Sep. 13, 2013) “Antibody Therapeutics in Cancer”, Science, 341(6151):1192-1198.
[cited by applicant]
Thaventhiran et al. (Oct. 17, 2012) “T Cell Co-inhibitory Receptors: Functions and Signalling Mechanisms”, Journal of Clinical & Cellular immunology, 12 pages.
[cited by applicant]
Tomalia (1993) “Starburst/Cascade Dendrimers: Fundamental Building Blocks for a New Nanoscopic Chemistry Set”, Aldrichimica Acta, 26(4):91-101.
[cited by applicant]
Urlaub et al. (Jul. 1980) “Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity”, PNAS, 77(7):4216-4220.
[cited by applicant]
Voet et al. Biochemistry John Wiley & Sons, Inc., (1990), pp. 126-128 and 228-234.
[cited by applicant]
Wahl et al. (1987) “Molecular Hybridization of Immobilized Nucleic Acids: Theoretical Concepts and Practical Considerations”, Methods in Enzymology, 152:399-407.
[cited by applicant]
Waldmann (Aug. 2006) “The Biology of Interleukin-2 and Interleukin-15: Implications for Cancer Therapy and Vaccine Design”, Nature Reviews Immunology, 6(8):595-601.
[cited by applicant]
Wang et al. (2015, e-published on Sep. 8, 2014) “T Cell-Based Targeted immunotherapies for Patients with Multiple Myeloma”, International Journal of Cancer, 136:1751-1768.
[cited by applicant]
Weidle et al. (Jul.-Aug. 2013) “The Emerging Role of New Protein Scaffold-based Agents for Treatment of Cancer”, Cancer Genomics and Proteomics, 10(4):155-168.
[cited by applicant]
Whitlow et al. (Apr. 1991) “Single-Chain Fv Proteins and their Fusion Proteins”, Methods: A Companion to Methods in Enzymology, 2(2):97-105.
[cited by applicant]
Wong et al. (Nov. 2013) “The IL-15-based Superagonist ALT-803 Promotes the Antigen-Independent Conversion of Memory CD8+ T Cells into innate-like Effector Cells with Antitumor Activity”, Oncolmmunology, 2(11):e26442-3 p…
[cited by applicant]
Wu et al. (Aug. 2010) “IL-15R Alpha-IgG1-Fc Enhances IL-2 and IL-15 Anti-Tumor Action Through NK and CD8+ T Cells Proliferation and Activation”, Journal of Molecular Cell Biology, 2(4):217-222.
[cited by applicant]
Xu, Wenxin, et al. “Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor? Su/Fc fusion complex in syngeneic murine models of multiple myeloma.” Cancer research 73(10), May 3, …
[cited by applicant]
Yoon et al. (2000) “Charged Residues Dominate a Unique Interlocking Topography in the Heterodimeric Cytokine Interleukin-12”, The EMBO Journal, 19(14):3530-3541.
[cited by applicant]
Zhu et al. (Sep. 15, 2009) “Novel Human Interleukin-15 Agonists”, Journal of Immunology, 183(6):3598-3607.
[cited by applicant]